New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood Within Just 12 Minutes
|
By HospiMedica International staff writers Posted on 10 Feb 2021 |

Image: New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood within Just 12 Minutes (Photo courtesy of American Chemical Society)
A new rapid COVID-19 test to detect coronavirus antibodies beats the enzyme linked immunosorbent assay (ELISA) method in delivering results within just 12 minutes, marking a milestone in the development of immunological diagnostics.
An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.
The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.
In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.
“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”
“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”
Related Links:
University of Paraná
University of Tübingen
An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.
The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.
In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.
“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”
“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”
Related Links:
University of Paraná
University of Tübingen
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Tool Speeds Echocardiogram Reporting With Comparable Accuracy
Echocardiography is the most widely used form of cardiac imaging, playing a key role in diagnosing heart disease and guiding treatment decisions. However, reviewing ultrasound images and documenting cardiac... Read more
AI Tool Improves Hospital Discharge Summaries to Support Follow-Up Care
Discharge summaries guide care after hospitalization but can be difficult to prepare after long or complex stays. Clinicians must condense treatment, medications, follow-up, and unresolved issues into... Read moreCritical Care
view channel
Studies Support AI-ECG for Detecting Suspected Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is frequently underdiagnosed despite being an important cause of cardiac morbidity. Routine 12-lead electrocardiograms are widely available in emergency, inpatient, and perioperative... Read more
Personalized fMRI-Guided TMS May Improve Severe OCD Symptoms
Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder marked by intrusive thoughts and repetitive behaviors. Severe cases can remain difficult to manage when medication and psychotherapy... Read moreSurgical Techniques
view channel
Researchers Develop Microbots to Help Drugs Reach Blood Clots
Blood clots can obstruct vessels supplying the brain, heart, or lungs, potentially causing stroke, myocardial infarction, or pulmonary embolism. Although catheter-delivered thrombolytic drugs can help... Read more
First Stemless Reverse Shoulder Arthroplasty System Receives FDA Clearance in U.S.
Reverse shoulder arthroplasty is evolving as surgeons look beyond traditional stemmed humeral fixation. Concepts that engage proximal humeral bone near cortical boundaries may avoid diaphyseal stems in... Read morePatient Care
view channelVirtual Reality Program May Reduce Anxiety Before Pediatric Surgery
Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more
Video-Based Support Helps Older Adults Clarify Kidney Disease Treatment Preferences
Advanced chronic kidney disease (CKD) involves progressive loss of kidney function that can lead to kidney failure and difficult treatment decisions. For older adults, these decisions may include choosing... Read moreMedical Imaging
view channel
MRI-Guided Focused Ultrasound Improves Motor Symptoms in Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that can cause tremor, muscle stiffness, slowed movement and medication-related involuntary movements. These symptoms can limit daily function... Read more
AI Tool Reconstructs Missing Brain Connectivity Data
Diffusion MRI helps map nerve fiber pathways in the brain, but some scans lose signal in regions that are important for understanding connectivity. These gaps can affect areas such as the brainstem and... Read moreHealth IT
view channel
Clinical Decision Support Tool Automates CKD Risk Assessment in Primary Care
Chronic kidney disease (CKD) requires timely diagnosis, risk assessment, and coordinated treatment in primary care. Delayed recognition can affect decisions about testing, blood pressure control, cardiovascular... Read more
EHR Alerts Support Dosing, Sedation, and Shock Recognition in Cardiac Care
Electronic health record alerts can add to clinician workload when they are poorly targeted. In critical cardiac care, however, delayed decisions can affect treatment timing, sedation exposure, and escalation... Read morePoint of Care
view channel
New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read moreBusiness
view channel
Healthcare Partnership Creates Testbed for Advanced Connectivity and AI Applications
Hospitals face growing care complexity, aging populations, and pressure to extend monitoring beyond traditional inpatient settings. Meeting these demands requires more responsive clinical workflows and... Read more
Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal
Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Stryker Enters Soft-Tissue Robotics Through Strategic Alliance With CMR Surgical
Stryker (Portage, MI, USA) and CMR Surgical (Cambridge, UK) have announced a strategic alliance centered on the Versius Surgical Robotic portfolio. The agreement includes an approximately USD 400 million... Read more








